May 2008
Volume 49, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2008
Role of Intravitreal Bevacizumab (Avastin) in the Management of Peripapillary Choroidal Neovascular Membrane
Author Affiliations & Notes
  • S. Patil
    Ophthalmology, Frimley Park Hospital, Frimley, United Kingdom
  • S. Pilli
    Ophthalmology, Frimley Park Hospital, Frimley, United Kingdom
  • D. Mathapati
    Ophthalmology, Frimley Park Hospital, Frimley, United Kingdom
  • M. Chandran
    Ophthalmology, Frimley Park Hospital, Frimley, United Kingdom
  • G. Ansari
    Ophthalmology, Frimley Park Hospital, Frimley, United Kingdom
  • S. Mackenzie
    Ophthalmology, Frimley Park Hospital, Frimley, United Kingdom
  • J. Jarzabek
    Ophthalmology, Frimley Park Hospital, Frimley, United Kingdom
  • G. Menon
    Ophthalmology, Frimley Park Hospital, Frimley, United Kingdom
  • Footnotes
    Commercial Relationships  S. Patil, None; S. Pilli, None; D. Mathapati, None; M. Chandran, None; G. Ansari, None; S. Mackenzie, None; J. Jarzabek, None; G. Menon, None.
  • Footnotes
    Support  None.
Investigative Ophthalmology & Visual Science May 2008, Vol.49, 328. doi:https://doi.org/
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      S. Patil, S. Pilli, D. Mathapati, M. Chandran, G. Ansari, S. Mackenzie, J. Jarzabek, G. Menon; Role of Intravitreal Bevacizumab (Avastin) in the Management of Peripapillary Choroidal Neovascular Membrane. Invest. Ophthalmol. Vis. Sci. 2008;49(13):328. doi: https://doi.org/.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract
 
Purpose:
 

To assess the effects of intravitreal bevacizumab as a primary treatment for peripapillary choroidal neovascularization (CNV) threatening the fovea.

 
Methods:
 

Data for three consecutive patients with sight threatening peripapillary CNV that were treated with intravitreal bevacizumab (1.25mg) injection were reviewed retrospectively. Main outcome measures included best-corrected visual acuity (BCVA), central macular thickness (CMT) measured by optical coherence tomography (OCT) and complete resolution of CNV at 12,24 and 52 weeks.

 
Results:
 

Over a mean follow-up period of 10 months(range, 6-12 months), 2 eyes received 2 injections and 1 eye required 3 injections at 6-weekly intervals to ensure complete resolution of the CNV. The CNV resolved completely in all the affected eyes (100%). The BCVA improved in 1 eye from logmar 0.8 to 0.2 and remained stable in the other 2 eyes, log mar 1.0 pre and post treatment. The CMT(graph1) decreased significantly (p<0.001) after the treatment. No adverse events occured.

 
Conclusions:
 

Intravitreal bevacizumab injection was found to be a safe and effective treatment option for peripapillary CNV in this case series with a one-year follow-up. It is difficult to conduct randomized clinical trials for this condition, but this case-series suggests the need for further case-series with larger sample size to assess the benefits of bevacizumab in this condition.  

 
Keywords: choroid: neovascularization • aging: visual performance • vascular endothelial growth factor 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×